Effects of empagliflosin and vildagliptin on structural and functionak parametres in patients with type 2 diabetes

Objective. To study the effect of empagliflozin and vildagliptin therapy on endothelial function and arterial stiffness parameters in type 2 diabetes mellitus (2DM) patients without previous cardiovascular events. Design and methods. We studied 34 patients with type 2DM without previous cardiovascular events, which initiated therapy with empagliflozin and 11 patients with type 2DM who received vildagliptin. At baseline and 24 weeks after the treatment, we assessed anthropometric parameters, endothelial function, arterial stiffness, central pressure parameters. We also performed ultrasound examination of the carotid arteries and echocardiography for evaluation of the left ventricular myocardial mass index. The effect of empagliflozin and vildagliptin on the structural and functional parameters of vascular wall was assessed. Results. Empagliflozin unlike vildagliptin treatment significantly improved endothelial function after 24 weeks of treatment (p < 0,05). Conclusions. Empagliflozin seems to possess a specific capacity to improve endothelial function.

empagliflozin, vildagliptin, endothelial function, arterial stiffness, type 2 diabetes mellitus

1. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl.1):S1–93.

2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.

3. Lunder M, Janic M, Sabovic M. Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall. Curr Vasc Pharmacol. 2018;17(1):6–15. doi: 10.2174/1570161116666180206113755

4. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55 (13):1318–1327.

5. Nilsson P, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526.

6. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303.

7. Van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077.

8. Shah Z, Pineda C, Kampfrath T, Maiseyu A, Ying Z, Racoma I et al. Acute DPP-4 inhibition modulates tone through GLP- 1 independent pathways. Vascular Pharmacol. 2011;55 (1–3):111–117.

9. Schmieder R, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P et al. Effects of the DPP-4 inhibitor saxagliptin on early vascular changes in the retinal and systemic circulation. Eur Heart J. 2013;34(suppl.1):607. https://doi.org/10.1093/urheartj/eht307.P607

10. Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14 (7):561–567.

11. Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AF et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13(18):2581–2591.

12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):21172128.

13. Vasyuk YA, Ivanova SV, Shkolnik EL, Kotovskaya YV, Milyagin VA, Oleynikov VE et al. Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention. 2016;15(2):4–19. doi: 10.15829/17288800-2016-2-4-19. In Russian.

14. Pignoli P, Longo T. Evaluation of atherosclerosis with B-mode ultrasound imaging. J Nucl Med Allied Sci. 1988;32 (3):166–173.

15. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(3, Suppl.):1156–1165.

16. Tentolouris A, Eleftheriadou I, Tzeravini E, Tsilingiris D, Paschou SA, Siasos G et al. Endothelium as a therapeutic target in diabetes mellitus: from basic mechanisms to clinical practice. Curr Med Chem. 2019. doi: 10.2174/0929867326666190119154152

17. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg Bet al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369:13171326.

18. White WB., Bakris GL., Bergenstal RM, Cannon CP, Cushman WC, Fleck P et al, Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620–626

19. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.

20. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. doi: 10.1056/NEJMoa1504720.

21. Lunder M, Janić M, Japelj M, Juretič A, Janež A, Šabovič M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153. doi: 10.1186/s12933-018-0797-6

22. Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44. doi: 10.1186/s12933019-0839-8

23. Kubota Y, Miyamoto M, Takagi G, Ikeda T, KirinokiIchikawa S, Tanaka K et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–1370. doi: 10.3346/jkms.2012.27.11.1364

24. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337–1344.

25. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 (14):1317–1326. doi: 10.1056/NEJMoa1307684

26. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889

27. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(6):232–242. doi: 10.1056/NEJMoa1501352

28. Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, PROLOGUE Study Investigators. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med. 2016;13 (6):e1002051. doi: 10.1371/journal.pmed.1002051

29. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, SAIS Study Group. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PloS One. 2016;11(10):e0164255. doi: 10.1371/journal.pone.0164255

30. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077. doi: 10.2337/dc10-2421

31. Cosenso-Martin LN, Giollo-Júnior LT, Fernandes LAB, Cesarino CB, Nakazonek MA, de Nassau Machado M et al. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: A randomized controlled trial. Acta Diabetologica. 2018;55 (12):1237–1245.

32. Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 2017;16(1):125. doi: 10.1186/s12933-0170607-6